Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Wilate (von Willebrand factor and coagulation factor VIII) promotes platelet aggregation and platelet adhesion on damaged vascular endothelium for the treatment and control of bleeding episodes and perioperative management of bleeding.
Lead Product(s): Human Von Willebrand Factor/Coagulation Factor VIII Complex
Therapeutic Area: Genetic Disease Product Name: Wilate
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 21, 2023
Details:
Octaplas® is human pooled plasma for infusion of pharmaceutical grade with standardised quality and unique safety profiles used for indications such as in hepatic failure or massive transfusion, substitution therapy in coagulation factor deficiencies etc.
Lead Product(s): Human Pooled Plasma
Therapeutic Area: Rare Diseases and Disorders Product Name: Octaplas
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 02, 2023
Details:
wilate® (human von willebrand factor/coagulation factor VIII complex) is a high-purity human VWF/FVIII concentrate, that undergoes two virus inactivation steps during its production. No albumin is added as a stabiliser.
Lead Product(s): Human Von Willebrand Factor/Coagulation Factor VIII Complex
Therapeutic Area: Genetic Disease Product Name: Wilate
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2022
Details:
Octagam (human immune globulin) 10% is a liquid preparation of highly purified human immunoglobulin for intravenous administration. The results of the study demonstrated that octagam® 10% is an efficacious and well-tolerated treatment for adults with dermatomyositis.
Lead Product(s): Human Immune Globulin
Therapeutic Area: Immunology Product Name: Octagam
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2022
Details:
OCTA101, (a human-cl rhFVIII and recombinant human von Willebrand Factor fragment dimer/OCTA8) a recombinant FVIII developed for subcutaneous administration in adult patients with severe haemophilia A.
Lead Product(s): OCTA8,OCTA12
Therapeutic Area: Genetic Disease Product Name: OCTA101
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 04, 2022
Details:
U.S. FDA Office of Orphan Products Development has awarded seven years of marketing exclusivity for Octagam® 10%, the first and only intravenous immunoglobulin (IVIg) to be indicated for the treatment of adult dermatomyositis.
Lead Product(s): Human Immune Globulin
Therapeutic Area: Immunology Product Name: Octagam
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 30, 2021
Details:
NUWIQ is a recombinant antihemophilic factor [coagulation factor VIII] indicated in adults and children with Hemophilia A for treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes.
Lead Product(s): Simoctocog Alfa
Therapeutic Area: Genetic Disease Product Name: Nuwiq
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 05, 2021
Details:
MOTIVATE trial comprised regimens of human cell line-derived recombinant FVIII Nuwiq® or the plasma-derived FVIII products octanate® or wilate® for the management of patients with hemophilia A and inhibitors.
Lead Product(s): Simoctocog Alfa
Therapeutic Area: Genetic Disease Product Name: Nuwiq
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: Hämophilie-Zentrum Rhein Main
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 28, 2021
Details:
The supplement approvals resulted in new product labeling for Octaplas™, Pooled Plasma (Human), Solvent/Detergent (S/D) Treated Solution for Intravenous Infusion, and fibryga®, Fibrinogen (Human) Lyophilized Powder for Reconstitution.
Lead Product(s): Human fibrinogen
Therapeutic Area: Hematology Product Name: Fibryga
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 29, 2021
Details:
The NuProtect study was a prospective, multinational, open-label, non-controlled phase III study initiated in March 2013 to assess the immunogenicity, efficacy and safety of Nuwiq®.
Lead Product(s): Simoctocog Alfa
Therapeutic Area: Genetic Disease Product Name: Nuwiq
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 22, 2021